AstraZeneca

AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
  • TickerAZN
  • ISINGB0009895292
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom

Analysts

Emira Sagaama ...
  • Jean Sassus
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Oussema Denguir
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/11/2019

...

Emira Sagaama ...
  • Jean Sassus
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Oussema Denguir
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 11/11/2019

...

Martial Descoutures ...
  • Oussema Denguir

AstraZeneca : Reassuring results for Roxadustat

>Good efficacy and reassuring safety profile - AstraZeneca presented at the end of last week the full results for its Olympus and Rockies studies at the ASN Kidney Week 2019 meeting. These two reports aimed to evaluate one of the group’s future blockbusters, i.e. Roxadustat for patients suffering from chronic kidney failure (treated or not by dialysis). We already know in both cases that the primary endpoint had been reached, i.e. a statistically significant improveme...

Martial Descoutures ...
  • Oussema Denguir

AstraZeneca : Des résultats rassurants pour Roxadustat

>Une bonne efficacité et une sécurité rassurante - AZN présentait en fin de semaine dernière les résultats complets de ses études Olympus et Rockies lors du congrès ASN 2019. Ces deux études avaient pour but d’évaluer un futur blockbuster du groupe à savoir Roxadustat chez les patients souffrant d’insuffisance rénale chronique (traités ou non par dialyse). Nous savions dans les deux cas que le critère primaire était atteint à savoir une amélioration statistiquement si...

Nurhayati Wan

AstraZeneca PLC

Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023 (Simplified Chinese translation)

企业融资部 Moody's France SAS96 Boulevard Haussmann Paris, 75008 France 联系电话. Moody's France SAS 96 Boulevard Haussmann Paris, 75008 France 联系电话. *请注意新闻稿之英文原版已于巴黎时间 9 月 24 日发放.

Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023

Announcement: Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023. Global Credit Research- 24 Sep 2019. -Relaxed regulation, improving healthcare coverage to drive China's pharmaceutical demand.

Moody's announces completion of a periodic review of ratings of AstraZeneca PLC

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of AstraZeneca PLC. Global Credit Research- 24 Sep 2019. Paris, September 24, 2019-- Moody's Investors Service has completed a periodic review of the ratings of AstraZeneca PLC and other ratings that are associated with the same analytical unit.

Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023

Announcement: Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023. Global Credit Research- 24 Sep 2019. -Relaxed regulation, improving healthcare coverage to drive China's pharmaceutical demand.

AstraZeneca PLC: Farxiga’s strong results in patients with heart failure could expand usage into a new substantial market

Credit implications of latest phase III trial for Farxiga

Martial Descoutures ...
  • Oussema Denguir

AstraZeneca : Reassuring results for Roxadustat

>Good efficacy and reassuring safety profile - AstraZeneca presented at the end of last week the full results for its Olympus and Rockies studies at the ASN Kidney Week 2019 meeting. These two reports aimed to evaluate one of the group’s future blockbusters, i.e. Roxadustat for patients suffering from chronic kidney failure (treated or not by dialysis). We already know in both cases that the primary endpoint had been reached, i.e. a statistically significant improveme...

Martial Descoutures ...
  • Oussema Denguir

AstraZeneca : Des résultats rassurants pour Roxadustat

>Une bonne efficacité et une sécurité rassurante - AZN présentait en fin de semaine dernière les résultats complets de ses études Olympus et Rockies lors du congrès ASN 2019. Ces deux études avaient pour but d’évaluer un futur blockbuster du groupe à savoir Roxadustat chez les patients souffrant d’insuffisance rénale chronique (traités ou non par dialyse). Nous savions dans les deux cas que le critère primaire était atteint à savoir une amélioration statistiquement si...

Nurhayati Wan

AstraZeneca PLC

Nurhayati Wan

AstraZeneca PLC

Nurhayati Wan

AstraZeneca PLC

1 director bought

A director at AstraZeneca bought 8,500 shares at 5,800p and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Emira Sagaama ...
  • Jean Sassus
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Oussema Denguir
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/11/2019

...

Emira Sagaama ...
  • Jean Sassus
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Oussema Denguir
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 11/11/2019

...

Alexandre Iatrides ...
  • Alfred Glaser
  • Delphine Brault
  • Florent Laroche-Joubert
  • Jean Sassus
  • Manuel Martin, CEFA,CREA
  • Martial Descoutures
  • Oussema Denguir
  • Pierre Tegner
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/29/2019

...

Alexandre Iatrides ...
  • Alfred Glaser
  • Delphine Brault
  • Florent Laroche-Joubert
  • Jean Sassus
  • Manuel Martin, CEFA,CREA
  • Martial Descoutures
  • Oussema Denguir
  • Pierre Tegner
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 29/10/2019

...

Alfred Glaser ...
  • Baptiste Lebacq
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • François Maury
  • Georges Dieng
  • Johanna Jourdain
  • Louis Boujard, CFA
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Oussema Denguir
  • Philippe Ourpatian
  • Stephane Houri
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/24/2019

The PMIs highlight the economic slowdown, but since mid-August, there has been a clear shift towards value and cyclical stocks. This apparent contradiction reveals an implicit bet by investors on the imminent upward inflection of PMIs. We therefore examined the structure of relative performance when an inflection is observed. The latter does imply a sectoral movement in favour of financial stocks at the expense of defensive stocks. Today's PMI publication will therefore be key to deci...

ASTRAZENECA PLC. loses on its star level and is downgraded to Slightly Positive

The independent financial analyst theScreener just slightly lowered the general evaluation of ASTRAZENECA PLC. (GB), active in the Pharmaceuticals industry. The title has lost a star(s) at the fundamental level and now shows 2 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date September 10, 2019, the closing price was GBp 6,847.00 and its potential was estimated at GBp 7,919.82.

Nurhayati Wan

AstraZeneca

Nurhayati Wan

AstraZeneca

Nurhayati Wan

AstraZeneca

Nurhayati Wan

AstraZeneca

Tougher Sledding: Stocks Reach First Major Hurdles (GMR Weekly Notes -21 Jan 2019)

Markets This Week: Stocks: ConocoPhillips (COP); Apple (AAPL); AbbVie (ABBV); Nokia (NOK); AstraZeneca (AZN); Aurora Cannabis (ACB); General Electric (GE) Forex: EURCHF; USDRUB; AUDNZD Rates: EDZ9; 2s/10s; Bunds (GDBR10)

The 'Trap-Door'' and Other Formations; Stocks Point Lower Into Dec (GMR Weekly Notes - 26 Nov 2018)

Markets This Week: Stocks: S&P500 (SPX); DJIA (INDU); Financial Sector ETF (XLF); Goldman Sachs (GS); Dish Network (DISH); Palo Alto Networks (PANW); Microsoft (MSFT); AstraZeneca (AZN) Forex: Dollar Index (DXY); USDCNH; USDBRL Rates: 2s/5s/10s Fly (BF0205010); 5s/30s

GMR Weekly Notes - Week of 21 May 2018

Markets This Week: Stocks: Nvidia (NVDA); JD.com (JD); Charter Comm (CHTR); Facebook (FB); XLP; AstraZeneca (AZN) Rates: Gilts (GUKG10); US 10s/30s; EDZ9 FX: USDMXN; USDINT; USDZAR

MarketLine Department

Calithera Biosciences, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Calithera Biosciences, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Calithera Biosciences, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its compet...

Eric Le Berrigaud

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC

SECTOR | Pharmaceuticals | BG OncoDay 2019: clear upside in early-stage NSCLC At our Annual Oncology Day this year, two KOLs (i) summarized the key learnings from ASCO 2019 and (ii) focused specifically on the advances in lung cancer. Then, out of the five companies presenting, three did so in plenary sessions, and we report here the main messages they conveyed

MarketLine Department

Novo Nordisk A/S - Strategy, SWOT and Corporate Finance Report

Summary Novo Nordisk A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Novo Nordisk AS (Novo Nordisk or 'the company') is a pharmaceutical company that manufactures and develops biological medicines primarily focused on diabetes including both Type 1 and Type 2. Other therapy areas covered by the company include obesity, Atherosclerosis, Non-alcoholic steatoh...

MarketLine Department

H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report

H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report Summary H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights H. Lundbeck A/S (Lundbeck or 'the company') is a specialty pharmaceutical company primarily focusing on brain diseases. The company’s products are focused on treating depression/anxiety, Alzheimer’s disease, schizophrenia, alcoho...

MarketLine Department

Bayer AG - Strategy, SWOT and Corporate Finance Report

Bayer AG - Strategy, SWOT and Corporate Finance Report Summary Bayer AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Bayer (or 'the group') is a Germany-based global chemical and pharmaceutical business group. It operates in Asia Pacific, Europe, North America, Latin America, Africa, and the Middle East. Bayer is headquartered in Leverkusen, Germany. Scope ...

Expert Corporate Governance Service (ECGS)

AstraZeneca - AGM 26 April 2019

Item 2: Declare a Dividend  The proposed dividend is the same as that of the previous fiscal year. It has remained unchanged at $2.80 per share since 2015.  The Board maintains a progressive dividend policy and has the intention to maintain or grow the dividend each year with the aim of striking a balance between the interest of the business, financial creditors and shareholders. However, in the current year the dividend is not covered by earnings or free cash flow.  In fact, free cash flow has not been able to cover the dividend for five years in a row.  We recommend shareholders oppose.  I...

Astrazeneca PLC – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Dave Nicoski ...
  • Ross LaDuke

Global Equity Strategy

Global equities (MSCI ACWI) are testing 52-week lows as prices have been consolidating over the last 1-2 months. Investors' primary sources of angst continue to revolve around concerns of (1) the global shift toward tighter monetary policy and the potential for perceived policy missteps, (2) trade and tariffs, and (3) the potential negative effects both (1) and (2) may have on global growth. Comments from Fed Chair Powell that interest rates are “just below” the neutral rate and the 90-day tariff ceasefire agreement between the U.S. and China have not been able to calm the markets. In Europe, ...

Jérôme VINERIER

Analyse court terme - ASTRAZENECA : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 6 145,00 p et 6 502,00 p. La tendance serait invalidée sous le support à 5 100,00 p.

Jérôme VINERIER

Short term view - ASTRAZENECA : The background trend is clearly bullish.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at 6,145.00 p and 6,502.00 p. The trend would be invalidated below the support at 5,100.00 p.

Jérôme VINERIER

Analyse court terme - ASTRAZENECA : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 6 145,00 p. La rupture du support à 5 100,00 p invaliderait cette tendance.

Jérôme VINERIER

Short term view - ASTRAZENECA : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 6,145.00 p. Breaking below the support at 5,100.00 p would invalidate the trend.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch